Profound Medical Corp.

Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth

Profound Medical signed a supply and distribution agreement with Cook Medical's iMRI Division to expand U.S. sales of its TULSA-PRO system through Cook's Copernicus program and iMRI Suite offering. Cook will purchase TULSA-PRO systems at a predetermined transfer price for U.S. distribution, while Profound retains direct relationships for recurring single-use disposables and service contracts on systems sold through the channel. The deal complements Profound's existing co-sales agreement with Siemens Healthineers and is intended to increase system placements and grow the installed base generating recurring revenue.

•2d ago

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

Profound Medical announced five abstracts at the 15th Interventional MRI Symposium supporting the real-world performance and clinical differentiation of its TULSA-PRO system. The randomized CAPTAIN trial showed whole-gland TULSA was statistically superior to robotic radical prostatectomy at six months, with patients more than twice as likely to preserve both erectile function and pad-free continence (risk ratio 2.1, p=0.004). Real-world data from Mayo Clinic Florida (58 patients), Mayo Clinic Rochester (41 patients), and the 197-patient CARE Registry showed favorable functional outcomes and manageable safety profiles, though recurrence rates of 12-22% underscore ongoing oncologic-durability questions. Technical validation on Siemens' lower-cost 0.55T Free.Max MRI could eventually reduce infrastructure barriers to adoption, but the company cautioned this does not establish FDA clearance or commercial availability on the combined platform.

•18d ago

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Profound Medical entered a co-education agreement with Telix Pharmaceuticals to educate urologists, radiologists, and prostate cancer centers on combining Telix's PSMA-PET imaging (Gozellix, Illuccix) with Profound's MRI-guided TULSA-PRO platform. The deal gives Profound increased access to urologists via Telix's channels and aims to support patient selection and expand the TULSA Procedure's addressable market, including potentially broadening candidacy for higher-risk patients. Profound is also developing PSMA-PET–MR image-fusion for a future TDC software release, which management believes could become a key differentiator versus ultrasound-registered competitor approaches.

•23d ago

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

Profound Medical announced preliminary unaudited Q3 2026 revenue of $9.8-$10.0 million, a record quarter that is 45-47% above the Bloomberg consensus of $6.78 million. Growth is up approximately 85-89% year-over-year from $5.3 million and roughly 292-300% sequentially from $2.5 million, with gross margin again expected to exceed 70%. Full results are due after market close on November 5, 2026, with a 4:30 p.m. ET conference call; figures are preliminary and unaudited.

•25d ago

Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

Profound Medical appointed Richard Fabian as President, effective immediately, succeeding Mathieu Burtnyk who transitions to the newly created role of Chief Technology Officer. Fabian brings over 29 years of industry experience, most recently serving as CEO of FUJIFILM Sonosite and holding prior executive roles at Philips Healthcare. CEO Arun Menawat emphasized the move as a strategic step to sharpen execution and profitable growth while retaining Burtnyk to lead clinical innovation.

•2mo ago

Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’

Profound Medical introduced its new Treatment Delivery Console (TDC) software for its TULSA-PRO system, deploying it across the installed base. The upgrade features real-time iMRI control and interface improvements aimed at reducing planning complexity and enhancing physician control. Management believes the update provides a roadmap to increase daily procedure throughput from up to four to potentially six procedures per surgeon.

•2mo ago

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

Profound Medical launched Let's Huddle, a global patient community designed to support men and their families throughout the prostate care journey through education and connection. Led by former NFL player Leonard Wheeler, the initiative aims to empower patients with resources and peer support to navigate complex treatment decisions. The program reinforces the company's commitment to patient-centered care alongside its TULSA-PRO and Sonalleve technologies.

•2mo ago

Profound Medical Reports Second Quarter 2026 Financial Results

Profound Medical reported Q2 revenue of $2.5 million, up 12% year-over-year, though approximately $3.1 million of shipments shifted into Q3 due to a temporary logistics issue; excluding this timing difference, revenue would have grown 153%. The company demonstrated significant operating leverage with operating expenses declining 16% and net loss improving by 39% to $9.5 million, while gross margin expanded to 78%. Management reiterated its full-year 2026 revenue guidance of $25.0 million, citing record new orders of $7.0 million and a qualified sales pipeline valued at roughly $70.0 million.

•2mo ago

Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026

Profound Medical announced it will have a significant presence at the Society of Robotic Surgery Annual Meeting in Fort Lauderdale from July 23-26, featuring multiple presentations on the TULSA Procedure's clinical outcomes. The company was selected as one of only eight firms for the Society of Incisionless Surgery plenary session and will host an investor event moderated by analysts from Stifel and Wells Fargo. Presentations will cover data from the CAPTAIN randomized trial and real-world efficacy, including UT Southwestern's achievement of a 100-procedure milestone in 2022.

•3mo ago